欧盟 - 捷克文 - EMA (European Medicines Agency)

viatris limited - pirfenidon - idiopathic pulmonary fibrosis; lung diseases; respiratory tract diseases - imunosupresiva - pirfenidone viatris is indicated in adults for the treatment of mild to moderate idiopathic pulmonary fibrosis (ipf).

欧盟 - 捷克文 - EMA (European Medicines Agency)

viatris limited - dapagliflozin - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - léky užívané při diabetu - type 2 diabetes mellitusdapagliflozin viatris is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance. - in addition to other medicinal products for the treatment of type 2 diabetes. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 a 5. heart failuredapagliflozin viatris is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction. chronic kidney diseasedapagliflozin viatris is indicated in adults for the treatment of chronic kidney disease.

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 10mg - bisoprolol

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 2,5mg - bisoprolol

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 10087 bisoprolol-fumarÁt - potahovaná tableta - 5mg - bisoprolol

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

theramex ireland limited, dublin array - 6073 dydrogesteron - potahovaná tableta - 10mg - dydrogesteron

欧盟 - 捷克文 - EMA (European Medicines Agency)

viatris limited - klopidogrel besilate - peripheral vascular diseases; stroke; myocardial infarction - antitrombotické činidla - secondary prevention of atherothrombotic events clopidogrel is indicated in:adult patients suffering from myocardial infarction (from a few days until less than 35 days), ischemic stroke (from 7 days until less than 6 months) or established peripheral arterial disease. adult patients suffering from acute coronary syndrome. non-st segment elevation acute coronary syndrome (unstable angina or non-q-wave myocardial infarction), including patients undergoing a stent placement following percutaneous coronary intervention, in combination with acetylsalicylic acid (asa). st elevace akutního infarktu myokardu, v kombinaci s asa u medikamentózně léčených pacientů vhodných pro trombolytickou terapii. in patients with moderate to high-risk transient ischaemic attack (tia) or minor ischaemic stroke (is) clopidogrel in combination with asa is indicated in:adult patients with moderate to high-risk tia (abcd2 score ≥4) or minor is (nihss ≤3) within 24 hours of either the tia or is event. prevention of atherothrombotic and thromboembolic events in atrial fibrillation:in adult patients with atrial fibrillation who have at least one risk factor for vascular events, are not suitable for treatment with vitamin k antagonists (vka) and who have a low bleeding risk, clopidogrel is indicated in combination with asa for the prevention of atherothrombotic and thromboembolic events, including stroke. pro další informace viz bod 5.

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 12990 amlodipin-besilÁt - tableta - 10mg - amlodipin

捷克共和国 - 捷克文 - SUKL (Státní ústav pro kontrolu léčiv)

viatris limited, dublin array - 12990 amlodipin-besilÁt - tableta - 5mg - amlodipin

欧盟 - 捷克文 - EMA (European Medicines Agency)

viatris healthcare limited - tolkaponu - parkinsonova choroba - anti-parkinson drogy, další dopaminergní léčiva - tasmar je indikován v kombinaci s levodopou / benserazid nebo levodopa / karbidopa pro použití u pacientů s levodopou reagovat idiopatická parkinsonova nemoc a motorickými neodpověděl na nebo netolerují jiné inhibitory katechol o-metyltransferázy (comt). kvůli riziku potenciálně fatální, akutní poškození jater, je přípravek tasmar by neměl být považován za první linii levodopa / benserazid nebo levodopa / karbidopa. protože tasmar by měla být použita pouze v kombinaci s levodopou / benserazidem nebo levodopou / karbidopou, předepisování informace pro tyto přípravky obsahujícími levodopu je také použitelné pro jejich současné užívání s přípravkem tasmar.